Psylo is a pre-clinical biotech company designing new therapeutics to treat mental illness. By developing novel molecules inspired by psychedelic chemotypes they aim to discover next generation medicines which iterate on what exists in nature. Psylo's first initiative is to produce a shorter acting psilocybin derivative to expand the therapeutic application of psychedelic medicine.